ALKS 7119

Drug Profile

ALKS 7119

Alternative Names: ALKS7119

Latest Information Update: 04 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes plc
  • Class Antidepressants; Nootropics
  • Mechanism of Action NMDA receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Agitation

Most Recent Events

  • 01 Oct 2016 Discontinued - Phase-I for Agitation (In volunteers) in Netherlands, USA (PO) due to unfavourable tolerability results (Alkermes plc 10-K, February 2017)
  • 01 Oct 2016 Discontinued - Preclinical for Agitation in Ireland (PO) due to unfavourable tolerability results (Alkermes plc 10-K, February 2017)
  • 28 Apr 2016 Alkermes plans a phase I multiple ascending dose study in Agitation (In volunteers) (NTR5956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top